These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2209 related items for PubMed ID: 19096301

  • 1. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [Abstract] [Full Text] [Related]

  • 2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 3. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T.
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [Abstract] [Full Text] [Related]

  • 4. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 5. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.
    J Thorac Oncol; 2009 Jan 01; 4(1):22-9. PubMed ID: 19096302
    [Abstract] [Full Text] [Related]

  • 6. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
    J Thorac Oncol; 2012 Oct 01; 7(10):1490-502. PubMed ID: 22982650
    [Abstract] [Full Text] [Related]

  • 7. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP.
    J Thorac Oncol; 2008 Apr 01; 3(4):331-9. PubMed ID: 18379349
    [Abstract] [Full Text] [Related]

  • 8. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.
    Tumori; 2007 Apr 01; 93(5):473-7. PubMed ID: 18038880
    [Abstract] [Full Text] [Related]

  • 9. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F.
    Am J Clin Oncol; 2014 Aug 01; 37(4):343-9. PubMed ID: 23357969
    [Abstract] [Full Text] [Related]

  • 10. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z, Xiaomei L, Aiping Z, Jianbo H, Xiangqun S, Qitao Y.
    Genes Chromosomes Cancer; 2012 Oct 01; 51(10):925-32. PubMed ID: 22736493
    [Abstract] [Full Text] [Related]

  • 11. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.
    Anticancer Res; 2013 Apr 01; 33(4):1705-11. PubMed ID: 23564819
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.
    Clin Lung Cancer; 2014 Jan 01; 15(1):86-92. PubMed ID: 24139827
    [Abstract] [Full Text] [Related]

  • 13. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M.
    J Thorac Oncol; 2008 Apr 01; 3(4):365-73. PubMed ID: 18379354
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C, Negri FV, Azzoni C, Naldi N, Nizzoli R, Bortesi B, Zobbi V, Bottarelli L, Tiseo M, Silini EM, Ardizzoni A.
    Diagn Cytopathol; 2013 Jul 01; 41(7):595-8. PubMed ID: 22833420
    [Abstract] [Full Text] [Related]

  • 15. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
    Yamaguchi F, Kugawa S, Tateno H, Kokubu F, Fukuchi K.
    Lung Cancer; 2012 Dec 01; 78(3):201-6. PubMed ID: 23026641
    [Abstract] [Full Text] [Related]

  • 16. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J.
    Int J Cancer; 2009 Nov 15; 125(10):2393-9. PubMed ID: 19530244
    [Abstract] [Full Text] [Related]

  • 17. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT, Chang JW, Liu HP, Yu TF, Chiu YT, Hsieh JJ, Chen YT, Chen YR, Wu HD, Huang SF.
    J Thorac Oncol; 2011 Dec 15; 6(12):2027-35. PubMed ID: 22052229
    [Abstract] [Full Text] [Related]

  • 18. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y.
    Cancer Genet; 2013 Dec 15; 206(9-10):330-9. PubMed ID: 24200637
    [Abstract] [Full Text] [Related]

  • 19. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD, Labiano T, Echeveste J, Gurpide A, Martín-Algarra S, Zhang G, Sharma A, Palma JF.
    Cancer Cytopathol; 2015 Apr 15; 123(4):230-6. PubMed ID: 25529460
    [Abstract] [Full Text] [Related]

  • 20. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.
    Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF.
    J Thorac Oncol; 2010 Aug 15; 5(8):1175-84. PubMed ID: 20559151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 111.